{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:13:31Z","timestamp":1781594011366,"version":"3.54.5"},"reference-count":36,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00480","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T04:05:45Z","timestamp":1500350745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries"],"prefix":"10.3389","volume":"8","author":[{"given":"Ambra","family":"Villari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giurdanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bucolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"34803","DOI":"10.1074\/jbc.M110.163642","article-title":"Factor X\/Xa elicits protective signaling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment of PAR-1.","volume":"285","author":"Bae","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"34730","DOI":"10.1074\/jbc.273.52.34730","article-title":"Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex.","volume":"273","author":"Berry","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","article-title":"Factor Xa: at the crossroads between coagulation and signaling in physiology and disease.","volume":"14","author":"Borensztajn","year":"2008","journal-title":"Trends Mol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology.","volume":"3","author":"Coughlin","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bcp.2015.05.017","article-title":"Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2\/COX-2\/VEGF-A pathway.","volume":"96","author":"Giurdanella","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40265-016-0644-6","article-title":"Apixaban: a review in venous thromboembolism.","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1161\/hh1301.092661","article-title":"Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists.","volume":"89","author":"Hamilton","year":"2001","journal-title":"Circ. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1124\/pr.54.2.203","article-title":"International union of pharmacology. XXVIII. Proteinase-activated receptors.","volume":"54","author":"Hollenberg","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1182\/blood-2014-03-565010","article-title":"New insights into the spatiotemporal localization of prothrombinase in vivo.","volume":"124","author":"Ivanciu","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1085\/jgp.201511477","article-title":"Contributions of protein kinases and beta-arrestin to termination of protease-activated receptor 2 signaling.","volume":"147","author":"Jung","year":"2016","journal-title":"J. Gen. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cardiores.2003.11.030","article-title":"Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery.","volume":"61","author":"Kawabata","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.bjp.0705433","article-title":"Involvement of EDHF in the hypotension and increased gastric mucosal blood flow caused by PAR-2 activation in rats.","volume":"140","author":"Kawabata","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-62","article-title":"Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice.","volume":"10","author":"Li Volti","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11203","DOI":"10.1074\/jbc.M112.439950","article-title":"Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits beta-arrestin-mediated endosomal signaling.","volume":"288","author":"Lin","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14756366.2010.535793","article-title":"Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.","volume":"26","author":"Luettgen","year":"2011","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/hh0402.105372","article-title":"Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia\/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers.","volume":"90","author":"McLean","year":"2002","journal-title":"Circ. Res."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00133","article-title":"A new paradigm shift in antithrombotic therapy.","volume":"4","author":"Pudusseri","year":"2013","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/jcb.23427","article-title":"Determinants of the specificity of protease-activated receptors 1 and 2 signaling by factor Xa and thrombin.","volume":"113","author":"Rana","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1161\/01.ATV.0000184770.01494.2e","article-title":"Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes.","volume":"25","author":"Roviezzo","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.bcp.2014.10.011","article-title":"Regulation of vascular tone in rabbit ophthalmic artery: cross talk of endogenous and exogenous gas mediators.","volume":"92","author":"Salomone","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12028-008-9153-0","article-title":"Inhibition of cerebral vasoconstriction by dantrolene and nimodipine.","volume":"10","author":"Salomone","year":"2009","journal-title":"Neurocrit. Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/01.RES.81.5.824","article-title":"Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta.","volume":"81","author":"Schaeffer","year":"1997","journal-title":"Circ. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1164\/ajrccm.164.7.2101157","article-title":"Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle.","volume":"164","author":"Schmidlin","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2016.03.027","article-title":"What are they waiting for?-Tethered agonism in G protein-coupled receptors.","volume":"108","author":"Schoneberg","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/FJC.0b013e3181daded3","article-title":"Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis.","volume":"55","author":"Schumacher","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/01.STR.29.7.1439","article-title":"Activation of protease-activated receptor-2 (PAR-2) elicits nitric oxide-dependent dilatation of the basilar artery in vivo.","volume":"29","author":"Sobey","year":"1998","journal-title":"Stroke"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/01.str.30.9.1933","article-title":"Evidence for selective effects of chronic hypertension on cerebral artery vasodilatation to protease-activated receptor-2 activation.","volume":"30","author":"Sobey","year":"1999","journal-title":"Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.bbadis.2016.01.017","article-title":"EPAS1\/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells.","volume":"1862","author":"Stavik","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1476-5381.2011.01610.x","article-title":"Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).","volume":"165","author":"Suen","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jb\/117.2.244","article-title":"Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets.","volume":"117","author":"Sugo","year":"1995","journal-title":"J. Biochem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1124\/jpet.103.052100","article-title":"Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking.","volume":"307","author":"Trejo","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"F891","DOI":"10.1152\/ajprenal.00233.2001","article-title":"PAR-2 elicits afferent arteriolar vasodilation by NO-dependent and NO-independent actions.","volume":"282","author":"Trottier","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1517\/14656566.2015.999043","article-title":"Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.","volume":"16","author":"Vanassche","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.","volume":"6","author":"Wong","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"B36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","article-title":"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.","volume":"31","author":"Wong","year":"2011","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T04:05:45Z","timestamp":1500350745000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":36,"alternative-id":["10.3389\/fphar.2017.00480"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00480","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"article-number":"480"}}